Contact Us
Drug Search Results
More Filters [+]

Celiprolol

Alternative Names: celiprolol, EDSIVO
Latest Update: 2024-06-04
Latest Update Note: Clinical Trial Update

Product Description

Celiprolol is a beta 1-selective adrenoceptor antagonist (beta-blocker) which acts as a weak agonist at beta 2-adrenoceptors. The drug demonstrates vasodilator properties and does not depress heart rate to the same extent as propranolol, atenolol or metoprolol. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8573993/#:~:text=Celiprolol%20is%20a%20beta%201,as%20propranolol%2C%20atenolol%20or%20metoprolol.)

Mechanisms of Action: ADRB1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Ehlers-Danlos Syndrome *

Approval Status: Not Approved

Approved Countries: Bangladesh | Belgium | Chile | Colombia | Czech | Egypt | Finland | France | Germany | Greece | Hungary | India | Ireland | Italy | Korea | Lithuania | Netherlands | New Zealand | Peru | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Switzerland | Tunisia | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Acer Therapeutics
Company Location: NEWTON MA 02458
Company CEO: Chris Schelling
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Celiprolol

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Ehlers-Danlos Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DiSCOVER

P3

Recruiting

Ehlers-Danlos Syndrome

2029-03-01

72%

Recent News Events

Date

Type

Title

04/29/2024

News Article

 Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

12/30/2023

PubMed

 Sneezing-Induced Subclavian Arterial Rupture: A Case of Vascular Ehlers-Danlos Syndrome in a Child.

12/16/2023

PubMed

 Despite celiprolol therapy, patients with vascular Ehlers-Danlos syndrome remain at risk of vascular events: A 12-year experience in an Italian referral center.

12/01/2023

PubMed

 Celiprolol and sympatho-immune interface in COVID-19.

11/20/2023

News Article

 Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

11/02/2023

News Article

 Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals

09/25/2023

News Article

 Celiprolol Hydrochloride Market 2023 Share, Strategies, Investment Opportunities, Industry Impact and Global Forecast till 2030

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions